Qi Wu

Dr. Qi Wu

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
QWQi Wu
Qi Wu
YCYanmin Chen
Yanmin Chen
MZMenglin Zhou
Menglin Zhou
MLMengting Liu
Mengting Liu
LZLixia Zhang
Lixia Zhang
DCDanqing Chen
Danqing Chen
Objectives: To evaluate the influence of genetic variants and clinical characteristics on the risk of gestational diabetes mellitus (GDM) and to construct and verify a prediction model of GDM in early pregnancy. Methods: Four hundred seventy five women with GDM and 487 women without, as a control, were included to construct the prediction model of GDM in early pregnancy. Both groups had complete genotyping results and clinical data. They were randomly divided into a trial cohort (70%) and a test cohort (30%). Then, the model validation cohort, including 985 pregnant women, was used for the external validation of the GDM early pregnancy prediction model. Results: We found maternal age, gravidity, parity, BMI and family history of diabetes were significantly associated with GDM (OR > 1; P < 0.001), and assisted reproduction was a critical risk factor for GDM (OR = 1.553, P = 0.055). MTNR1B rs10830963, C2CD4A/B rs1436953 and rs7172432, CMIP rs16955379 were significantly correlated with the incidence of GDM (AOR > 1, P < 0.05). Therefore, these four genetic susceptible single nucleotide polymorphisms (SNPs) and six clinical characteristics were included in the construction of the GDM early pregnancy prediction model. In the trial cohort, a predictive model of GDM in early pregnancy was constructed, in which genetic risk score was independently associated with GDM (AOR = 2.061, P < 0.001) and was the most effective predictor with the exception of family history of diabetes. The ROC-AUC of the prediction model was 0.727 (95% CI 0.690–0.765), and the sensitivity and specificity were 69.9% and 64.0%, respectively. The predictive power was also verified in the test cohort and the validation cohort. Conclusions: Based on the genetic variants and clinical characteristics, this study developed and verified the early pregnancy prediction model of GDM. This model can help screen out the population at high-risk for GDM in early pregnancy, and lifestyle interventions can be performed for them in a timely manner in early pregnancy.

1 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
LZLixia Zhang
Lixia Zhang
QWQi Wu
Qi Wu
SZShuqi Zhu
Shuqi Zhu
YTYibo Tang
Yibo Tang
YCYanmin Chen
Yanmin Chen
ZLZhaoxia Liang
Zhaoxia Liang
Gestational diabetes mellitus (GDM) leads to poor pregnancy outcomes and fetoplacental endothelial dysfunction; however, the underlying mechanisms remain unknown. This study aimed to investigate the effect of placenta-derived exosomal miRNAs on fetoplacental endothelial dysfunction in GDM, as well as to further explore the role of chemerin to this end. Placenta-derived exosomal miR-140-3p and miR-574-3p expression (next-generation sequencing, quantitative real-time PCR), its interactions with cell function (Cell Counting Kit-8, Transwell, tube formation assay), chemerin interactions (Western blotting), and placental inflammation (immunofluorescence staining, enzyme-linked immunosorbent assay) were investigated. Placenta-derived exosomal miR-140-3p and miR-574-3p were downregulated in GDM. Additionally, miR-140-3p and miR-574-3p inhibited the proliferation, migration, and tube formation ability of umbilical vein endothelial cells by targeting vascular endothelial growth factor. Interestingly, miR-140-3p and miR-574-3p expression levels were negatively correlated with chemerin, which induced placental inflammation through the recruitment of macrophage cells and release of IL-18 and IL-1β. These findings indicate that chemerin reduces placenta-derived exosomal miR-140-3p and miR-574-3p levels by inducing placental inflammation, thereby promoting the proliferation, migration, and tube formation of umbilical vein endothelial cells in GDM, providing a novel perspective on the underlying pathogenesis and therapeutic targets for GDM and its offspring complications.

4 July 2023 in Nutrition & Diabetes
Verified
Journal Article
Open access
PDF file
QWQi Wu
Qi Wu
YCYunyan Chen
Yunyan Chen
HMHao Ma
Hao Ma
TZTao Zhou
Tao Zhou
YHYing Hu
Ying Hu
DCDanqing Chen
Danqing Chen
Objectives: The gestational weight gain (GWG) and hyperglycemia are two key factors affecting adverse pregnancy outcomes among women with gestational diabetes mellitus (GDM). We aimed to investigate the combinatorial effect of abnormal glucose metabolism and GWG on adverse outcomes in GDM. Methods: This retrospective cohort study included 2611 pregnant women with GDM in Women’s Hospital School of Medicine Zhejiang University. Bases on the OGTT glucose levels, we categorized the GDM cohort into three subgroups: impaired fasting glucose (IFG) group, impaired glucose tolerance (IGT) group, and combined impaired glucose (IFG&IGT) group. Results: Among pregnant women with IGT, insufficient GWG (IGWG) was an independent protective factor for pregnancy-induced hypertension syndrome (PIH) (aOR 0.55, 95% CI 0.32-0.95), macrosomia (0.38, 0.19-0.74) and large for gestational age (0.45, 0.32-0.62), as well as an independent risk factor for low birth weight infants (2.29, 1.24-4.22) and small for gestational age (1.94, 1.17-3.19); and excessive GWG (EGWG) was related to increased risks of PIH (1.68, 1.12-2.52), preterm delivery (1.82, 1.28-2.58), postpartum hemorrhage (1.85, 1.05–3.28), cesarean delivery (1.84, 1.38-2.46) and low body weight infants (2.36, 1.33-4.20). Moreover, EGWG was positively associated with PIH (3.27, 1.09–9.80) in the IFG group. But there were no significant associations between either IGWG or EGWG and any pregnancy outcomes in women with combined IFG&IGT. Conclusions: The relationships between GWG and adverse outcomes were modified by abnormal glucose metabolism in women with GDM. Our results suggest that more specific GWG recommendations according to their metabolic state are needed for GDM.

5 March 2019 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
QWQi Wu
Qi Wu
LZLixia Zhang
Lixia Zhang
LHLicong Huang
Licong Huang
YLYu Lei
Yu Lei
LCLin Chen
Lin Chen
DCDanqing Chen
Danqing Chen

11 December 2025 in Nature Communications
Verified
Journal Article
Open access
QWQi Wu
Qi Wu
YWYihui Wu
Yihui Wu
SZShuqi Zhu
Shuqi Zhu
YTYibo Tang
Yibo Tang
LZLixia Zhang
Lixia Zhang
ZLZhaoxia Liang
Zhaoxia Liang
Gestational diabetes mellitus (GDM) is a common metabolic disorder in pregnancy, but the underlying mechanism has not been fully clarified. Using metabolomic profiling of second-trimester saliva, serum, and urine, we identify 54 metabolites altered in GDM that converge on key metabolic pathways. Fifty GDM biomarkers independently associated with abnormal maternal glucose and insulin resistance are selected to construct GDM discriminant models (internal test AUC: 0.868; real-world test: 0.796). These GDM biomarkers are also associated with clinical profiles and adverse outcomes, thereby predicting maternal and neonatal risks (internal test AUC: 0.764 and 0.838; real-world test: 0.726 and 0.792, respectively). Eleven GDM biomarkers are already altered in the first trimester, which can be used for the early prediction of GDM (internal test AUC: 0.767; real-world test: 0.744). In this work, changes and interactions of metabolites in saliva, serum, and urine in the second trimester are first identified in GDM, providing insights into its pathogenesis and potential early prediction and prevention strategies.

25 April 2021 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Open access
YCYunyan Chen
Yunyan Chen
QWQi Wu
Qi Wu
LZLixia Zhang
Lixia Zhang
DCDanqing Chen
Danqing Chen
ZLZhaoxia Liang
Zhaoxia Liang
目的 探讨妊娠期糖尿病(gestational diabetes mellitus,GDM)患者孕中期75g口服葡萄糖耐量试验(oral glucose tolerance test ,OGTT)血糖指标异常项数及孕期增重对妊娠结局的影响。方法 纳入2017年7月1日至2018年6月30日在浙江大学医学院附属妇产科医院定期产前检查并分娩的2611例GDM孕妇,根据孕中期OGTT血糖异常项数分为GDM I组(1项升高)、GDM II组(2项升高)和GDM III组(3项均升高),根据孕期体重增长分为增重不足组、增重适宜组及增重过多组,分析各组不良妊娠结局及两者的交互作用。结果 (1)GDM III组妊娠期高血压疾病、早产、巨大儿和大于胎龄儿(large for gestational age,LGA)发生率明显高于GDM II组、GDM I组;GDM Ⅱ组妊娠期高血压疾病和早产发生率也明显高于GDM I组。(2)孕期增重过多组妊娠期高血压疾病、巨大儿发生率明显高于增重不足及增重适宜组,LGA发生率明显高于增重不足组;增重适宜组早产和低出生体重儿发生率明显低于增重不足组及增重过多组,小于胎龄儿 (small for gestational age, SGA)发生率明显低于增重不足组。(3)在GDM I组,孕期增重不足是发生早产、SGA的危险因素(OR 2.04,95%CI 1.42-2.93;OR 2.09,95%CI 1.17-3.73),是妊娠期高血压疾病、LGA的保护因素(OR 0.55,95%CI 0.31-0.97;OR 0.50,95%CI 0.37-0.68);孕期增重过多则是妊娠期高血压疾病、低出生体重儿的危险因素(OR 1.82,95%CI 1.11-2.98;OR 2.34,95%CI 1.01-5.39)。在GDMⅡ组中,孕期增重不足是巨大儿和LGA的保护因素(OR 0.38,95%CI 0.18-0.80;OR 0.50,95%CI 0.34-0.73)。而在GDM Ⅲ组中孕期增重与不良妊娠结局的发生无明显关联。结论 在GDM孕期管理中,对于OGTT一项或两项血糖升高孕妇,孕期体重合理管理可降低部分不良妊娠结局的发生风险;三项血糖均升高孕妇,除了孕期体重管理,需更严格的血糖监测并进行药物降糖等积极干预措施。